Form 4: Scholar Rock CSO Granted 29,258 RSUs

Scholar Rock Holding Corp's Chief Scientific Officer, Mo Qatanani, was granted 29,258 restricted stock units as part of an equity compensation plan.

Summary

• Mo Qatanani, Chief Scientific Officer of Scholar Rock Holding Corp, acquired 29,258 restricted stock units (RSUs).
• The transaction date for this acquisition was February 9, 2026.
• These RSUs are subject to time-based vesting conditions, with each RSU representing the contingent right to receive one share of the company's common stock upon vesting.
• The shares will vest in four annual installments over four years, with the first installment vesting on January 15, 2027, and subsequent installments vesting annually thereafter, contingent on continued service.
• Following this transaction, Mo Qatanani beneficially owns a total of 114,918 RSUs.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting standard executive compensation practices aimed at long-term retention and alignment of interests, without indicating any immediate operational or financial shifts.

Positives

• The grant of 29,258 restricted stock units (RSUs) to the Chief Scientific Officer serves as a long-term incentive, aligning management's interests with shareholder value creation.
• The four-year vesting schedule promotes executive retention and commitment to the company's long-term success.

Negatives

• No immediate cash value is realized by the Chief Scientific Officer from this RSU grant, as the shares are subject to future vesting conditions.

Risks

• The value of the RSUs is tied to the future performance of Scholar Rock Holding Corp's common stock, meaning the ultimate value realized by the CSO could be lower than anticipated if the stock price declines.
• The vesting is contingent on continued service, posing a risk of forfeiture if the reporting person's employment terminates before vesting dates.

Future Outlook

The RSU grant signifies a long-term commitment to the Chief Scientific Officer, aiming to incentivize sustained performance and align executive interests with the company's future growth and shareholder returns over the next four years.

Industry Context

StockSavvy.ai notes that equity grants, particularly Restricted Stock Units (RSUs), are a standard component of executive compensation packages in the biotechnology and pharmaceutical industries. This practice is widely adopted to attract, retain, and motivate key scientific and executive talent, linking their personal financial success directly to the company's long-term stock performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for executive compensation is a common practice across the biotechnology and pharmaceutical sectors, comparable to companies like Biogen Inc. or Vertex Pharmaceuticals Inc., which frequently utilize similar equity-based incentives to align executive interests with long-term shareholder value.
• A four-year vesting schedule, with annual installments, is a typical structure for such grants, providing a sustained incentive for executive retention and performance, consistent with industry benchmarks for senior leadership.

Related Party Transactions

• The grant of 29,258 Restricted Stock Units (RSUs) to Mo Qatanani, the Chief Scientific Officer, constitutes a related party transaction as it involves compensation from the company to an executive officer.

Stakeholder Impact

• Shareholders: Potential for future dilution as RSUs convert to common stock, but also improved alignment of executive incentives with long-term shareholder value.
• Employees: May signal stability in executive leadership and a commitment to retaining key talent.

Next Steps

• The RSUs will vest in four annual installments, with the first installment on January 15, 2027.
• Subsequent installments will vest annually thereafter, contingent on the reporting person's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event (RSU grant) and does not provide sufficient information to warrant a change in investment recommendation. It reflects standard corporate governance and incentive practices, aligning executive interests with long-term company performance, but does not present new material information regarding operational performance or strategic direction that would alter a seasoned investor's current stance on the stock.

Keywords

Scholar Rock Holding Corp, SRRK, Form 4, Restricted Stock Units, RSU, Insider Transaction, Executive Compensation, Equity Grant, Chief Scientific Officer, Mo Qatanani